PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
94.56%
Some net income increase while CRON.TO is negative at -44.68%. John Neff would see a short-term edge over the struggling competitor.
11.63%
Some D&A expansion while CRON.TO is negative at -3.59%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-202.02%
Negative yoy deferred tax while CRON.TO stands at 59.63%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
6.78%
SBC growth well above CRON.TO's 1.46%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-620.50%
Both reduce yoy usage, with CRON.TO at -103.34%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-235.07%
AR is negative yoy while CRON.TO is 158.94%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
10.99%
Inventory shrinking or stable vs. CRON.TO's 89.70%, indicating lean supply management. David Dodd would confirm no demand shortfall.
-1393.26%
Both negative yoy AP, with CRON.TO at -2831.68%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
214.93%
Some yoy usage while CRON.TO is negative at -74.90%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-112.88%
Negative yoy while CRON.TO is 553.11%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-1372.80%
Both yoy CFO lines are negative, with CRON.TO at -21.79%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
24.61%
CapEx growth well above CRON.TO's 35.49%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-100.00%
Negative yoy acquisition while CRON.TO stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while CRON.TO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
323.81%
Proceeds from sales/maturities above 1.5x CRON.TO's 100.00%. David Dodd would confirm if the firm is capitalizing on strong valuations or freeing liquidity for expansions.
-112.16%
Both yoy lines negative, with CRON.TO at -102.24%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-1298.68%
We reduce yoy invests while CRON.TO stands at 44.98%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
39.55%
We repay more while CRON.TO is negative at -10.45%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
100.00%
Issuance growth of 100.00% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.